NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

NCT04621227

CompletedPhase 1

Sponsor: Pfizer

Conditions: Obesity

Interventions: PF-06882961, Rosuvastatin, Midazolam

Countries: United States

A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Body Mass Index (BMI) ≥ 30.0 kg/m2 and not more than 45.4 kg/m2 at Screening.
* Stable body weight, defined as \<5 kg change (per participant report) for 90 days before Screening

Exclusion Criteria:

* Known prior participation in a trial involving PF-06882961.
* Known intolerance or hypersensitivity to GLP-1R agonists.
* Known hypersensitivity to rosuvastatin or midazolam.
* Diagnosis of type 1 or type 2 diabetes mellitus or secondary forms of diabetes at screening. Note: prior diagnoses of gestational diabetes during pregnancy only are eligible if they meet the other eligibility criteria
* Any lifetime history of a suicide attempt.
* Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
* Participation in a formal weight reduction program (eg, Weight Watchers) within 90 days prior to Screening.

Locations (1)

Anaheim, California, United States